UXT-V1 Facilitates the Formation of MAVS Antiviral Signalosome on Mitochondria

Yuefeng Huang, Heng Liu, Rui Ge, Yi Zhou, Xiwen Lou and Chen Wang

*J Immunol* published online 30 November 2011
http://www.jimmunol.org/content/early/2011/11/30/jimmunol.1102079

---

**Supplementary Material**
http://www.jimmunol.org/content/suppl/2011/11/30/jimmunol.1102079.DC1

**Subscription**
Information about subscribing to *The Journal of Immunology* is online at:
http://jimmunol.org/subscription

**Permissions**
Submit copyright permission requests at:
http://www.aai.org/About/Publications/JI/copyright.html

**Email Alerts**
Receive free email-alerts when new articles cite this article. Sign up at:
http://jimmunol.org/alerts
**uxt-v1 Facilitates the Formation of MAVS Antiviral Signalosome on Mitochondria**

**Yuefeng Huang,**¹ **Heng Liu,**¹ **Rui Ge, Yi Zhou, Xiwen Lou, and Chen Wang**

Virus infection induces the MAVS–TNFR-associated factor (TRAF) 3 signaling axis on mitochondria. It remains to elucidate the corresponding regulatory processes. In this study, we identify UXT-V1 as a novel TRAF3-binding protein. UXT-V1 is critical for the virus-induced activation of NF-κB and IFN regulatory factor 3. Reduction of UXT-V1 impairs the induction of IFN-β and attenuates the host antiviral responses. The N-terminal TRAF-binding motif of UXT-V1 binds to the C-terminal TRAF domain of TRAF3, thus facilitating the interaction between TRAF3 and MAVS. Notably, TRAF3 and TNFR-associated death domain protein are recruited onto mitochondria upon virus infection. These translocations are blocked when knocking down UXT-V1. Thus, UXT-V1 represents a novel integral component of the MAVS signalosome on mitochondria, mediating the innate antiviral signal transduction. The **Journal of Immunology**, 2012, 188: 000–000.

To initiate robust antiviral responses, the immune system must recognize pathogen-associated molecular patterns effectively (1, 2). The first family of pattern recognition receptor molecules identified are the TLRs, in which TLR3, TLR7/TLR8, and TLR9 are capable of detecting viral nucleic acids (3, 4). In contrast to TLRs that monitor the presence of topologically extracellular viruses in immune cells, RIG-I and MDA5 have been characterized as ubiquitous sensors for detecting cytosolic RNA viruses during primary responses of host cells (5–7).

Once RIG-I/MDA5 senses viral RNAs, a mitochondrial signalosome, which includes MAVS (also known as IPS1, VISA, and Cardif), TNFR-associated factor (TRAF) 3, TNFR-associated death domain protein (TRADD), and so on (8–13). This ultimately leads to the activation of TANK-binding kinase 1 (TBK1), which then phosphorylates IFN regulatory factor 3 (IRF3) and TBK1 at its C terminus. In turn, IRF3 dimerizes and translocates into nucleus (14). A dozen proteins have been reported to regulate this signaling pathway (15). In addition, the MAVS signalosome could activate the IκB kinase (IKK) complex and NF-κB. The transcription factors IRF3 and NF-κB synergistically induce the early production of type I IFNs and subsequent establishment of antiviral state (16, 17).

**MATERIALS AND METHODS**

**Reagents**

The anti-UXT mAb was provided by W. Krek (Swiss Federal Institute of Technology Zurich, Switzerland). The following Abs were used for Western blot or immunoprecipitation: Sp1 (S9809; Sigma-Aldrich), α-tubulin (T9206; Sigma-Aldrich), β-actin (A5316; Sigma-Aldrich), normal mouse IgG (sc-2025; Santa Cruz Biotechnology), normal rabbit IgG (sc-2337; Santa Cruz Biotechnology), hemagglutinin (HA; sc-7392, Santa Cruz Biotechnology; ab9110, Abcam), Flag (F1804; Sigma-Aldrich), TRAF6 (sc-8409; Santa Cruz Biotechnology), TRADD (sc-1828; Santa Cruz Biotechnology), TRAF2 (sc-876 and sc-7346; Santa Cruz Biotechnology; ab9110, Abcam), Flag (F1804; Sigma-Aldrich), TRAF3 (sc-1928; Santa Cruz Biotechnology), TRAF2 (sc-876 and sc-7346; Santa Cruz Biotechnology), TRAF6 (sc-8409; Santa Cruz Biotechnology), TRADD (sc-46653; Santa Cruz Biotechnology), Tom20 (11802-1-AP; Proteintech), caspase-3 (9662; Cell Signaling), cleaved caspase-3 (9661; Cell Signaling), and MAVS (3993; Cell Signaling). Polyinosinic-polycytidylic acid [poly(I:C)] was purchased from GE Healthcare and was used at 10 mg/ml.

**Materials and Methods**

**Reagents**

The anti-UXT mAb was provided by W. Krek (Swiss Federal Institute of Technology Zurich, Switzerland). The following Abs were used for Western blot or immunoprecipitation: Sp1 (S9809; Sigma-Aldrich), α-tubulin (T9206; Sigma-Aldrich), β-actin (A5316; Sigma-Aldrich), normal mouse IgG (sc-2025; Santa Cruz Biotechnology), normal rabbit IgG (sc-2027; Santa Cruz Biotechnology), hemagglutinin (HA; sc-7392, Santa Cruz Biotechnology; ab9110, Abcam), Flag (F1804; Sigma-Aldrich), TRAF3 (sc-1928; Santa Cruz Biotechnology), TRAF2 (sc-876 and sc-7346; Santa Cruz Biotechnology), TRAF6 (sc-8409; Santa Cruz Biotechnology), TRADD (sc-46653; Santa Cruz Biotechnology), Tom20 (11802-1-AP; Proteintech), caspase-3 (9662; Cell Signaling), cleaved caspase-3 (9661; Cell Signaling), and MAVS (3993; Cell Signaling). Polyinosinic-polycytidylic acid [poly(I:C)] was purchased from GE Healthcare and was used at 10 mg/ml.
TNF-α was obtained from R&D Systems. LPS was purchased from Invitrogen. Vesicular stomatitis virus (VSV) and Newcastle disease virus (NDV)-GFP were provided by H. Shu (Wuhan University) and Z. Bu (Chinese Academy of Agricultural Sciences), respectively.

**Cell culture and manipulation of primary cells**

HeLa, HEK293, HEK293T, NIH3T3, and RAW264.7 cell lines were obtained from the American Type Culture Collection and cultured according to the manufacturer’s instructions. Bone marrow-derived macrophages (BMDMs) were obtained, as described previously (29). BMDMs were harvested after ∼6–10 d and recultured in 12-well plates for small interfering RNA (siRNA) transfection using Lipofectamine 2000 (Invitrogen) and further experiments.

**Plasmids, siRNA oligos, and cell transfection**

Human or mouse UXT-V1 and TRAF3 cDNAs were amplified by RT-PCR from total RNA of HEK293T cells or NIH3T3 cells, respectively. The siRNA oligos against UXT-V1 were synthesized by GenePharma (human UXT-V1 siRNA, 5′-GGC UGA ACC UCC AGC UUG ATT-3′; mouse UXT-V1 siRNA, 5′-GAA GGU UAA AUA GAG CCG UT-3′). The cells were transfected with siRNA oligos using Lipofectamine 2000, and were incubated for 48 h before further analysis. In the rescue assay, the plasmids were introduced into cells after these cells were transfected with siRNAs for 24 h, and then were maintained for another 24 h before further analysis.

**Nuclear extraction**

Nuclear extractions of HEK293 cells were prepared, as described previously (30).

**Western blot and immunoprecipitation**

Cell pellet was collected and resuspended in radioimmunoprecipitation assay buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 0.25% Na-deoxycholate, 1 mM Na3VO4, 0.1 mM PMSF, Roche complete protease inhibitor set) for immunoprecipitation, or in RIPA buffer plus 0.1% SDS for Western blot. The resuspended cell pellet was vortexed for 20 s, then incubated on ice for 20 min, and...
centrifuged at 20,000 \times g for 15 min. The supernatants were collected for Western blot analysis or immunoprecipitation.

For immunoprecipitation, cell lysates were precleared with Protein A/G Plus-Agarose (Santa Cruz Biotechnology) at 4°C for 2 h, and then Ab or control IgG beads were added and incubated overnight. The next day, the cell lysates were incubated for another 2 h because the Protein A/G Plus-Agarose beads were added. The beads were washed with TBS buffer containing 0.5% Nonidet P-40; then the beads were boiled using 1× SDS loading buffer, and the supernatants were prepared for Western blot analysis.

Confocal microscopy

Twenty-four hours after being transfected with enhanced GFP-tagged plasmids, cells cultured on coverslips were fixed with 4% paraformaldehyde (Sigma-Aldrich), and nuclei were stained with DAPI (Sigma-Aldrich). Slides were mounted by Aqua-Poly/Mount coverslipping medium (Polysciences). Images were captured using a confocal microscopy (TCS SP2 AOBS; Leica) with an original magnification ×63 NA 1.4 oil objective.

Flow cytometry

Twelve hours after NDV-GVP infection, HEK293 cells were collected and washed by PBS buffer. Then the GFP-positive cells were measured using FACSCalibur (BD Biosciences), and the data were analyzed with Flowjo software.

Quantitative PCR

Total cellular RNA was isolated with TRIzol (Invitrogen), according to the manufacturer’s instructions. Reverse transcription of purified RNA was performed using oligo(dT) primer. The quantification of gene transcripts was performed by real-time PCR using SYBR Green PCR mix (Applied Biosystems). All values were normalized to the level of β-actin mRNA. The primers used were as follows. Primers for human: β-actin, sense (5’-AAA GAC CTG TAC GCC AAC AC-3’) and antisense (5’-GTC ATA CTC CTG CTT GCT GAT-3’); IFN-β, sense (5’-ATT GCC TCA AGG ACA GGA TG-3’) and antisense (5’-GCC CTT CAG GTA ATG CAG AA-3’); IL-8, sense (5’-AGG TGC AGT TTT GCC AAG GA-3’) and antisense (5’-TTT CGT TGT TGG CGC AGT GT-3’); and IFN-stimulated gene (ISG).
54, sense (5'-TGC AAC CTA CTG GCC TAT CTA-3') and antisense (5'-CAT GCC ACC CGG ATG ATT-3'). Primers for mouse: B-actin, sense (5'-AGA CCT TCA TGC CAA CAC AG-3') and antisense (5'-TAC TCC TGC ATG AT-3'); IFN-β, sense (5'-AGA TCA ACC AAG ACC AGG-3') and antisense (5'-GAG AGG AGA CCT CAC AGA GG-3'); and ISG56, sense (5'-AGT GCA GGC AGA AAT TCA CC-3') and antisense (5'-AGC AGT CAG TAG TTT CCA CC-3').

Subcellular fractionation
HEK293 cells were washed with cold PBS and lysed by Dounce homogenizer in homogenization buffer (210 mM sucrose, 70 mM mannitol, 1 mM EDTA, 1 mM EGTA, 1.5 mM MgCl2, 10 mM HEPES [pH 7.2]). The homogenate was centrifuged at 500 g for 10 min, and the pellet was discarded as crude nuclei. The supernatant was centrifuged at 5000 g for 10 min to precipitate crude mitochondria; then the supernatants were collected as cytosolic fraction, and the precipitate was lysed by RIPA buffer as mitochondria fraction.

Virus manipulation
Viral infection was performed when 80% cell confluence was reached. Then, culture medium was replaced by serum-free DMEM, and Sendai virus (SeV), VSV, or NDV-GFP was added to the media at multiplicity of infection (MOI) of 0.2–1, according to specific experiments. After 1 h, the medium was removed and the cells were fed with DMEM containing 10% FBS.

Results

**UXT-V1 binds to TRAF3 and is required for the activation of IRF3 and NF-κB**

There are two mRNA splicing isoforms of UXT in cells, which we name as UXT-V1 and UXT-V2, respectively. Previously, we characterized UXT-V2 as a novel transcriptional cofactor to regulate NF-κB in the nucleus (31). However, it came to our attention that those two isoforms represented different subcellular localization. Whereas UXT-V2 predominantly resided in nucleus, UXT-V1 was reproducibly found to localize in cytoplasm (Fig. 1A), which suggested that UXT-V1 could perform different functions from that of UXT-V2. Structurally, UXT-V1 (169 aa) harbored 12 more amino acids on its N terminus than UXT-V2 (157 aa). Through the Bioinformatics method, a potential TRAF-binding motif –TPQE was identified in the N terminus of UXT-V1. This consensus sequence, (P/S/A/T) X (Q/E) E, was previously identified in TRAF-binding proteins, such as CD40 and LTβR (Fig. 1B) (32–35). So we explored the possible interaction between UXT-V1 and TRAF family proteins. Interestingly, UXT-V1 could bind strongly to TRAF2 and TRAF3 (Fig. 1C). Our recent study explored the function of the UXT-V1–TRAF2 interaction and revealed that UXT-V1 was an important regulator of TNF-induced apoptosis (30).
In the current study, we went on to investigate the potential function of the UXT-V1–TRAFl3 interaction in innate immunity. To further verify this interaction, an exogenous immunoprecipitation assay was performed in HEK293T cells. Apparently, UXT-V1 could be coimmunoprecipitated with Flag-TRAFl3, whereas UXT-V2 could not (Fig. 1D). The endogenous interaction between UXT-V1 and TRAFl3 was also confirmed, and this interaction was enhanced upon SeV infection (Fig. 1E), indicating that UXT-V1 is a novel TRAFl3-binding protein.

Given the essential role of TRAFl3 in innate immunity, we screened out a siRNA that could specifically knock down UXT-V1 without affecting the UXT-V2 expression (Fig. 1F). To explore the potential function of UXT-V1 in antiviral signaling, it was observed that knockdown of UXT-V1 apparently inhibited the activation of the IFN-β luciferase reporter, stimulated by either SeV infection or poly(I:C) transfection (Fig. 1G). Consistently, the induction of κB (responsive to NF-κB) or PRDIII-1 (responsive to IRF3) luciferase reporters was attenuated when knocking down UXT-V1 (Fig. 2A). To make it more physiologically relevant, knockdown of UXT-V1 markedly impaired the induction of IFN-β, IL-6, and ISG56 in BMDMs, after stimulating by SeV infection or poly(I:C) transfection (Fig. 2B). These data indicate that UXT-V1 is a positive modulator of RIG-I–mediated IRF3 and NF-κB antiviral signaling.

Given that UXT-V1 regulates TNF-induced apoptosis, we wondered whether UXT-V1 could modulate SeV-induced apoptosis. As shown in Supplemental Fig. 1, cell apoptosis did not occur until 16 h after Sendai virus infection, whereas the IFNs were robustly induced within 6 h (Fig. 2A, 2B). Importantly, knockdown of UXT-V1 had no effect on SeV-induced apoptosis (Supplemental Fig. 1).
The TRAF-binding motif is essential for UXT-V1’s antiviral function

To delineate the topology of UXT-V1 in the RIG-I/MAVS/TBK1/IRF3 signaling pathway, we individually introduced the expressing plasmids of these four proteins into control cells or UXT-V1 knockdown cells for activating IFN-β luciferase reporter. Notably, knockdown of UXT-V1 attenuated the activation of IFN-β reporter in response to RIG-I or MAVS, but did not in response to TBK1 or IRF3-5D (Fig. 3A). Furthermore, UXT-V1 marginally bound to MAVS, and had no obvious interaction with RIG-I, TBK1, IKKe, or IKKa, although UXT-V1 interacted strongly with TRAF3 (Fig. 3B). This indicates that UXT-V1 acts downstream of RIG-I and MAVS and upstream of TBK1 and IRF3.

We went on to address the functional significance of the interaction between UXT-V1 and TRAF3. So, UXT-V1(3M) was generated, in which threonine (T), glutamine (Q), and glutamic acid (E) were all mutated to glycine (A) at residues 7, 9, and 10, respectively (Fig. 3C, upper). Interestingly, UXT-V1(3M) was deprived of the ability to interact with TRAF3 (Fig. 3C, lower), confirming that the N terminus of UXT-V1 was an authentic TRAF-binding motif toward TRAF3.

Then, the genetic rescue assays were performed in cells that had the endogenous UXT-V1 knocked down. As expected, wild-type (WT) UXT-V1 could significantly rescue the activation of IFN-β luciferase reporter stimulated by SeV infection. Notably, UXT-V1(3M) could not do so (Fig. 3D). Consistently, SeV-stimulated induction of the IFN-β, IL-8, or ISG54 was restored in the UXT-V1 knockdown cells, by introducing WT UXT-V1, but not by UXT-V1(3M) (Fig. 3E). Collectively, these data indicate that the TRAF-binding motif is essential for UXT-V1’s antiviral function.

**UXT-V1 facilitates the interaction between TRAF3 and MAVS**

To map the binding domain, we constructed four truncation mutants of TRAF3 (Fig. 4A). These truncation mutants were respectively transfected into HEK293T cells along with UXT-V1. As shown in Fig. 4B, the truncation mutant lacking the TRAF domain (∆T) failed to interact with UXT-V1, indicating that the TRAF domain of TRAF3 mediates its interaction with UXT-V1. Interestingly, a recent study also characterized that the TRAF domain of TRAF3 mediates its interaction with UXT-V1. Our data indicated that the TRAF-binding motif toward TRAF3.

To probe the relationship among UXT-V1, TRAF3, and MAVS, the immunoprecipitation assay was performed and revealed that UXT-V1 could markedly potentiate the interaction between TRAF3 and MAVS, whereas UXT-V1(3M) or UXT-V2 failed to do so (Fig. 4D). Importantly, knockdown of UXT-V1 apparently attenuated the endogenous interaction between TRAF3 and MAVS, indicating that UXT-V1 promotes the formation of MAVS–TRAF3 complex following virus infection (Fig. 4E). In contrast, the MAVS and TRAF3 interaction was not modulated by the TNF-α stimulation (Fig. 4F). In addition, knockdown of UXT-V1 had no effect on the MAVS–TRAF6 interaction (Supplemental Fig. 3A), and there was no detectable interaction between TRAF2 and MAVS under the stimulation of TNF-α or SeV (Supplemental Fig. 3B). These data indicate that UXT-V1 regulates MAVS antiviral signaling by targeting TRAF3.

**UXT-V1 facilitates the recruitment of TRAF3 and TRADD onto mitochondria**

Because MAVS is localized on the outer membrane of mitochondria, it is intriguing how TRAF3 and TRADD are recruited onto the MAVS signalosome. Subcellular fractionation was employed to monitor the locations of these proteins. In resting cells, TRAF3 or TRADD predominantly resided in the cytosolic fraction.

**FIGURE 5.** UXT-V1 facilitates the recruitment of TRAF3 and TRADD to mitochondria. A, HEK293 cells transfected with control or UXT-V1 siRNAs were stimulated with or without SeV for 1 h, and then the total cells and cytosolic and mitochondrial fractions were extracted for immunoblot of TRAF3, TRADD, MAVS, caspase-3, and Tom20. The levels of caspase-3 and Tom20 were applied to indicate accuracy of fractionation. *UXT-V2. B, HEK293 cells were stimulated with SeV or TNF-α for 1 h, and then the cytosolic and mitochondrial fractions were extracted for immunoblot of caspase-3, Tom20, and UXT-V1. C, The indicated plasmids were introduced into HEK293 cells. One hour after SeV infected, subcellular fractionation assay was performed and the corresponding fractions were subjected to Western blot assay of Flag, caspase-3, and Tom20.
lates innate antiviral responses. Notably, mitochondria-associated TRAF3 and TRADD were markedly increased following SeV treatment (Fig. 5A). More importantly, this phenomenon was abolished when silencing the endogenous UXT-V1 expression. In contrast, UXT-V1 apparently did not influence the presence of MAVS on mitochondria (Fig. 5A), suggesting that UXT-V1 modulates MAVS signalosome assemblage. In addition, UXT-V1 was present in the mitochondrial fraction upon SeV stimulation, but not upon TNF-α stimulation (Fig. 5B). This indicates that UXT-V1 is a novel component of the MAVS signalosome on mitochondria.

To further test this possibility, the TRAF3 (WT), TRAF3 (Y440A/Q442A), and TRAF3 (∆T) were respectively introduced into HEK293 cells, stimulated or not by SeV, followed by subcellular fractionation. Despite lacking the ability to bind MAVS, TRAF3 (Y440A/Q442A) could be recruited onto mitochondria, as well as TRAF3 (WT), upon SeV infection. However, TRAF3 (∆T), which could interact with neither MAVS nor UXT-V1, failed to be recruited onto mitochondria (Fig. 5C). Taken together, these data indicate that UXT-V1 facilitates the recruitment of TRAF3 to mitochondria.

**UXT-V1 modulates host antiviral responses**

Finally, we assessed the role of UXT-V1 in virus restriction. Crystal violet staining revealed that knockdown of UXT-V1 made cells more sensitive to VSV infection (Fig. 6A). In addition, the titers of VSV were analyzed by standard plaque assay. Knockdown of UXT-V1 resulted in ∼3-fold increase in virus titer as compared with the controls (Fig. 6B). We also investigated whether UXT-V1 modulated virus replication, by challenging cells with NDV-GFP. Consistently, NDV-GFP infection increased when knocking down UXT-V1 (Fig. 6C), and a 10-fold increase of NDV-GFP-positive cells was determined by flow cytometry assay (Fig. 6D). Taken together, these data demonstrate that UXT-V1 positively modulates innate antiviral responses.

**Discussion**

UXT is widely present in human and mouse tissues. Bioinformatics analysis reveals two isoforms of UXT, namely UXT-V1 and UXT-V2. Previous investigations characterize UXT-V2 to function in the nucleus. For example, UXT-V2 is suggested to interact with the N terminus of the androgen receptor and regulate androgen-responsive genes (36). UXT-V2 is also implicated as a component of the centrosome (37). Our recent study uncovers UXT-V2 to positively modulate the NF-κB transcriptional enhanceosome. Unexpectedly, we observe that UXT-V1 expresses almost exclusively in the cytoplasm, and the functional characterization of UXT-V1 has not been determined (30).

MAVS signalosome is an emerging antiviral protein complex on mitochondria. Recent studies have characterized several proteins important for this antiviral signaling. Current research aims to understand the MAVS complex protein composition, temporal and spatial dynamics, and mechanism of signal transduction. Intriguingly, MAVS forms prion-like aggregates on mitochondria to activate antiviral innate immune response (38). In this study, we have identified UXT-V1 as a novel component of the MAVS signalosome, and it is critical for the virus-induced activation of NF-κB and IRF3. Thus, UXT-V1 represents a novel integral component of the MAVS signalosome on mitochondria, mediating the innate antiviral signal transduction.

MAVS per se localizes on the outer membrane of mitochondria via its C-terminal transmembrane domain. In resting cells, most of the proteins in the MAVS signalosome reside in cytosol, including TRAF3 and TRADD. Upon virus infection, these proteins are proposed to quickly aggregate with MAVS on mitochondria (23, 28). Thus, a critical missing link exists as to how MAVS relays signals to these cytosolic proteins. A recent study suggested that K63 polyubiquitination of MAVS could serve as a signal for the assemblage of the protein complex (39). By subcellular fractionation assay, we demonstrate the specific translocation of TRAF3/TRADD onto mitochondria upon virus infection. It remains unknown whether TRAF3/TRADD could bind to the polyubiquitin chain.

![Figure 6](http://www.jimmunol.org/)
TRAF3 is essential for both RIG-I/MDA5 and TLR signaling during virus infection. A spontaneous mutation of TRAF3 (R118W) in humans leads to the impairment of TLR3-dependent induction of IFN and the susceptibility to HSV-1. The generation of TRAF3<sup>−/−</sup> BMDMs establishes that TRAF3 functions as a bridge between MAVs and the downstream TBK1/IKKε. The C-terminal 455-PEENEY-460 TRAF-binding motif of MAVs is critical for recruiting TRAF3. In addition, Triad3A could target TRAF3 for Lys<sub>48</sub>-linked ubiquitin-mediated degradation, and negatively regulates TRAF3-mediated NF-κB activation. TRAF3 negatively regulates the RIG-I/MAVS signaling pathway by targeting TRAF3 for degradation. Notably, the N-terminal TRAF-binding site in MAVS participates in positive and negative regulation of the IFN antiviral response. Cyto kine Growth Factor Rev. 18: 483–490.


